The Ahmedabad-based drug firm Zydus Cadila and Turkey-based leading healthcare firm, Eczacibasi Ilac Pazarlama have signed a pact to market biotech products in the Turkish market.
This collaboration will enable exchange products and expansion of geographies.
- The collaboration agreement involves the import of biosimilars that are currently unavailable in Turkey, especially for the treatment of cancer.
- The pact also paves way for a long-term collaboration to produce and launch new products in the Turkish market.
Biosimilars are copies of complex biological drugs. Unlike generic drugs that are cheaper copies of branded chemical drugs, biosimilars are harder and more expensive to develop as they are made from living cells and cannot be identically replicated.
- Turkey as an emerging market has witnessed immense progress in terms of regulations covering market approvals of biosimilars.
- In March 2016, Dr. Reddyâs Laboratories Ltd. had entered into a strategic collaboration agreement involving three biosimilar products with Turkey-based TR-Pharm.